On September 25, 2019, CorMedix reported that it has entered into a Letter Agreement with several holders (each a "Holder") of several Series B Warrants issued by us on May 3, 2017, and amended on September 20, 2019 (each, a "Letter Agreement") (Filing, 8-K, CorMedix, SEP 25, 2019, View Source [SID1234551862]). Pursuant to each Letter Agreement, we agreed to reduce the exercise price of each Holder’s Series B Warrant from $5.25 to $4.00, provided that each Holder exercised its Warrant for cash at the time of entry into such Letter Agreement. In accordance with each Letter Agreement, each Holder exercised its Series B Warrant in full and we issued an aggregate of 1,224,263 shares of common stock, par value $0.001 per share, and we received proceeds of $4,897,052.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!